Side effects and watch-outs
- Injection site pain (most common finding in trials)
- Fatigue
- Nausea
- Rare: hypotension
- Generally well tolerated in Phase 2 trials
Peptide / Longevity
SS-31 (Elamipretide)
Mitochondria-targeted tetrapeptide that protects cardiolipin integrity and reduces mitochondrial reactive oxygen species. Phase 2/3 trials for heart failure and mitochondrial disease (Barth syndrome).
Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.